|
1
|
Cancer incidence in five continents. VIII.
IARC Sci Publ; pp. 1–781. 2002
|
|
2
|
Schwartzbaum JA, Fisher JL, Aldape KD and
Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin
Pract Neurol. 2:494–503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maher EA, Furnari FB, Bachoo RM, et al:
Malignant glioma: genetics and biology of a grave matter. Genes
Dev. 15:1311–1333. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, et al:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krakstad C and Chekenya M: Survival
signalling and apoptosis resistance in glioblastomas: opportunities
for targeted therapeutics. Mol Cancer. 9:1352010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Poonnoose SI and Daniel RT: Radiological
evidence of glioma invasion of the central nervous system along
tracts. Surg Neurol. 54:194–196. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tate MC and Aghi MK: Biology of
angiogenesis and invasion in glioma. Neurotherapeutics. 6:447–457.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grossman SA and Batara JF: Current
management of glioblastoma multiforme. Semin Oncol. 31:635–644.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Preusser M, de Ribaupierre S, Wohrer A, et
al: Current concepts and management of glioblastoma. Ann Neurol.
70:9–21. 2011. View Article : Google Scholar
|
|
10
|
Zinn PO, Colen RR, Kasper EM and Burkhardt
JK: Extent of resection and radiotherapy in GBM: A 1973 to 2007
surveillance, epidemiology and end results analysis of 21,783
patients. Int J Oncol. 42:929–934. 2013.PubMed/NCBI
|
|
11
|
Yan H, Yang K, Xiao H, Zou YJ, Zhang WB
and Liu HY: Over-expression of cofilin-1 and phosphoglycerate
kinase 1 in astrocytomas involved in pathogenesis of
radioresistance. CNS Neurosci Ther. 18:729–736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
VandeBerg JL: The phosphoglycerate kinase
isozyme system in mammals: biochemical, genetic, developmental, and
evolutionary aspects. Isozymes Curr Top Biol Med Res. 12:133–187.
1985.PubMed/NCBI
|
|
13
|
Ahmad SS, Glatzle J, Bajaeifer K, et al:
Phosphoglycerate kinase 1 as a promoter of metastasis in colon
cancer. Int J Oncol. 43:586–590. 2013.PubMed/NCBI
|
|
14
|
Chen G, Gharib TG, Wang H, et al: Protein
profiles associated with survival in lung adenocarcinoma. Proc Natl
Acad Sci USA. 100:13537–13542. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zieker D, Konigsrainer I, Tritschler I, et
al: Phosphoglycerate kinase 1 a promoting enzyme for peritoneal
dissemination in gastric cancer. Int J Cancer. 126:1513–1520.
2010.PubMed/NCBI
|
|
16
|
Wang J, Ying G, Jung Y, et al:
Characterization of phosphoglycerate kinase-1 expression of stromal
cells derived from tumor microenvironment in prostate cancer
progression. Cancer Res. 70:471–480. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cecconi D, Palmieri M and Donadelli M:
Proteomics in pancreatic cancer research. Proteomics. 11:816–828.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duan Z, Lamendola DE, Yusuf RZ, Penson RT,
Preffer FI and Seiden MV: Overexpression of human phosphoglycerate
kinase 1 (PGK1) induces a multidrug resistance phenotype.
Anticancer Res. 22:1933–1941. 2002.PubMed/NCBI
|
|
19
|
Lincet H, Guevel B, Pineau C, et al:
Comparative 2D-DIGE proteomic analysis of ovarian carcinoma cells:
toward a reorientation of biosynthesis pathways associated with
acquired platinum resistance. J Proteomics. 75:1157–1169. 2012.
View Article : Google Scholar
|
|
20
|
Lin TY, Chang JT, Wang HM, et al:
Proteomics of the radioresistant phenotype in head-and-neck cancer:
Gp96 as a novel prediction marker and sensitizing target for
radiotherapy. Int J Radiat Oncol Biol Phys. 78:246–256. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
22
|
Rich JN and Bigner DD: Development of
novel targeted therapies in the treatment of malignant glioma. Nat
Rev Drug Discov. 3:430–446. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakamizo A, Marini F, Amano T, et al:
Human bone marrow-derived mesenchymal stem cells in the treatment
of gliomas. Cancer Res. 65:3307–3318. 2005.PubMed/NCBI
|
|
24
|
Hwang TL, Liang Y, Chien KY and Yu JS:
Overexpression and elevated serum levels of phosphoglycerate kinase
1 in pancreatic ductal adenocarcinoma. Proteomics. 6:2259–2272.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fantin VR, St-Pierre J and Leder P:
Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell.
9:425–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brizel DM, Dodge RK, Clough RW and
Dewhirst MW: Oxygenation of head and neck cancer: changes during
radiotherapy and impact on treatment outcome. Radiother Oncol.
53:113–117. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fyles AW, Milosevic M, Wong R, et al:
Oxygenation predicts radiation response and survival in patients
with cervix cancer. Radiother Oncol. 48:149–156. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Knocke TH, Weitmann HD, Feldmann HJ,
Selzer E and Potter R: Intratumoral pO2-measurements as
predictive assay in the treatment of carcinoma of the uterine
cervix. Radiother Oncol. 53:99–104. 1999.
|
|
29
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fujiwara S, Nakagawa K, Harada H, et al:
Silencing hypoxia-inducible factor-1α inhibits cell migration and
invasion under hypoxic environment in malignant gliomas. Int J
Oncol. 30:793–802. 2007.
|
|
31
|
Semenza GL, Roth PH, Fang HM and Wang GL:
Transcriptional regulation of genes encoding glycolytic enzymes by
hypoxia-inducible factor 1. J Biol Chem. 269:23757–23763.
1994.PubMed/NCBI
|
|
32
|
Lam W, Bussom S and Cheng YC: Effect of
hypoxia on the expression of phosphoglycerate kinase and antitumor
activity of troxacitabine and gemcitabine in non-small cell lung
carcinoma. Mol Cancer Ther. 8:415–423. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim JW and Dang CV: Cancer’s molecular
sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930.
2006.
|
|
35
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
|
|
36
|
Daly EB, Wind T, Jiang XM, Sun L and Hogg
PJ: Secretion of phosphoglycerate kinase from tumour cells is
controlled by oxygen-sensing hydroxylases. Biochim Biophys Acta.
1691:17–22. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lepleux C, Abeilard-Lemoisson E, Duval M,
Icard P and Lincet H: siPGK1 sensitizes chemoresistant human
ovarian cancer cell lines to cisplatin. Anticancer Res.
32:4277–4286. 2012.PubMed/NCBI
|
|
38
|
Bao S, Wu Q, McLendon RE, et al: Glioma
stem cells promote radioresistance by preferential activation of
the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
